FDA DEPENDING ON INDUSTRY TO DEVISE SYSTEM TO FIGHT COUNTERFEIT DRUGS

Executive Briefing Series
KEYWORDS FDA
A A

Despite urging industry to adopt electronic track-and-trace technologies over the next three years as part of a campaign against counterfeit drugs, FDA officials acknowledge they don’t know what the ultimate cost of such a move will be and are relying on market forces to drive the potential price of compliance to reasonable levels.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00